A SPAC Acquisition II in an 8-K said it has identified a potential business combination target company in the medical technology sector. The unnamed company is based in Taiwan.
The potential target specializes in microsphere technologies for ultrasound contrast agents that facilitate ultrasound imaging and ultrasound-mediated targeted delivery. The target “is believed to have developed a patented microbubble based contrast agent for the usage of early cancer screening and drug delivery in ultrasonic imaging,” the SPAC said in the filing.
Shareholders meet Aug. 1 to vote on an extension proposal.
The Singapore-based SPAC raised $185 million in a May 2022 IPO, initially to target Proptech and Fintech operations with a preference for companies that promote environmental, social and governance (“ESG”) principles. Read more.
